Morgan Stanley adds Amazon.com as Top Pick
Monogram Technologies Inc. (NASDAQ:MGRM), currently valued at $235 million, began distributing texts and emails to its shareholders Friday to inform them of the upcoming 2025 special meeting of stockholders. The purpose of the meeting is to vote on the proposed acquisition of Monogram Technologies by Zimmer Biomet Holdings, Inc., a transaction that was first announced on July 14, 2025. According to InvestingPro data, the stock has seen remarkable momentum, delivering a 148% return over the past six months.
According to a statement in a press release and SEC filing, the company sent notifications to both registered and street holders using multiple communication channels. Copies of the distributed texts and emails were included as exhibits to the filing.
Monogram Technologies, based in Austin, Texas, is incorporated in Delaware and trades its common stock on The Nasdaq Stock Market under the symbol MGRM. The company is classified under surgical and medical instruments and apparatus.
The company’s filing noted that the information provided, including the attached communications, is being furnished and will not be considered “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934. The notification process is part of the ongoing procedures related to the proposed acquisition.
This information is based on a statement from a press release and an SEC filing submitted Friday.
In other recent news, Monogram Technologies has made headlines with several significant developments. The company announced that Zimmer Biomet Holdings will acquire it for approximately $177 million in equity value. Under the terms of this agreement, Zimmer Biomet will pay $4.04 per share in cash to Monogram shareholders, who will also receive a contingent value right that could provide up to $12.37 per share if certain milestones are met by 2030. Additionally, Monogram amended its merger agreement with Zimmer Biomet, addressing a verbal comment from the Securities and Exchange Commission by modifying the definition of "Permitted Transfer" in the Contingent Value Rights Agreement.
To keep shareholders informed, Monogram released a set of frequently asked questions regarding the proposed acquisition. In another development, Monogram announced the termination of its Exclusive License Agreement with the Icahn School of Medicine at Mount Sinai. This termination included a settlement payment of $4 million, consisting of $500,000 in cash and 35,000 shares of newly created Series E Redeemable Perpetual Preferred Stock. These recent developments highlight significant changes and transactions involving Monogram Technologies.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.